Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Rating of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received an average rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.3333.

A number of research analysts have issued reports on the company. Wall Street Zen raised Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Finally, Rodman & Renshaw began coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price for the company.

Institutional Trading of Atossa Genetics

Several hedge funds have recently modified their holdings of ATOS. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics in the second quarter valued at approximately $2,468,000. Renaissance Technologies LLC grew its position in Atossa Genetics by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares during the last quarter. Jane Street Group LLC bought a new stake in Atossa Genetics during the 2nd quarter worth approximately $381,000. Qube Research & Technologies Ltd increased its holdings in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after purchasing an additional 245,717 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Trading Down 3.2%

ATOS stock opened at $2.42 on Wednesday. Atossa Genetics has a 1-year low of $1.70 and a 1-year high of $19.35. The business’s 50 day moving average is $2.36 and its 200-day moving average is $3.89. The firm has a market cap of $24.15 million, a P/E ratio of -0.78 and a beta of 1.27.

Atossa Genetics (NASDAQ:ATOS) last posted its earnings results on Friday, August 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.07. Sell-side analysts forecast that Atossa Genetics will post -3.95 EPS for the current year.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.